电刺激对肝癌患者化疗所致恶心呕吐的影响。
Effect of electrical stimulation for chemotherapy-induced nausea and vomiting in patients with liver cancer.
作者信息
Li Wei-Hong, Li Dong
机构信息
Department of Emergency Surgery, First Affiliated Hospital of Jiamusi University, Jiamusi.
Department of Hepatobiliary Surgery, The First People's Hospital of Xianyang City, Xianyang, China.
出版信息
Medicine (Baltimore). 2019 Apr;98(16):e15255. doi: 10.1097/MD.0000000000015255.
BACKGROUND
This study will be proposed for assessing the effects of electrical stimulation (ES) for chemotherapy-induced nausea and vomiting (CINV) in patients with liver cancer (LC).
METHODS
We will identify the relevant literatures of ES for CINV in patients with LC from following databases: Cochrane Library, PUBMED, EMBASE, Web of Science, the Cumulative Index to Nursing and Allied Health Literature, the Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from inception to the date of literature searched without any language restrictions. Randomized controlled trials and case-control studies on assessing of effects and safety of ES for CINV in patients with LC will be included. Methodological quality for all included studies will be assessed by using Cochrane risk of bias tool. RevMan 5.3 software (Cochrane Community, London, UK) will be used to analyze the data.
RESULTS
This study will summarize current evidence for ES on CINV in patients with LC. Primary outcome includes symptoms severity. Secondary outcomes consist of appetite, performance status, health-related quality of life, and adverse events.
CONCLUSION
The results of this study will provide latest evidence to judge the effects and safety for ES on CINV in patients with LC.
PROSPERO REGISTRATION NUMBER
PROSPERO CRD42019126379.
背景
本研究旨在评估电刺激（ES）对肝癌（LC）患者化疗引起的恶心和呕吐（CINV）的影响。
方法
我们将从以下数据库中检索关于ES治疗LC患者CINV的相关文献：Cochrane图书馆、PUBMED、EMBASE、科学网、护理及相关健康文献累积索引、补充与替代医学数据库、中国生物医学文献数据库和中国知网，检索时间从建库至文献检索日期，无语言限制。纳入评估ES治疗LC患者CINV的疗效和安全性的随机对照试验和病例对照研究。使用Cochrane偏倚风险工具评估所有纳入研究的方法学质量。采用RevMan 5.3软件（英国伦敦Cochrane协作网）进行数据分析。
结果
本研究将总结目前ES治疗LC患者CINV的证据。主要结局包括症状严重程度。次要结局包括食欲、体能状态、健康相关生活质量和不良事件。
结论
本研究结果将为判断ES治疗LC患者CINV的疗效和安全性提供最新证据。
PROSPERO注册号：PROSPERO CRD42019126379。
Zotero 插件